Tech Company Financing Transactions
Codiak BioSciences Funding Round
Codiak BioSciences secured a $76.5 million Series C funding round on 11/30/2017. Investors included Alaska Permanent Fund, Alexandria Venture Investments and Arch Venture Partners.
Transaction Overview
Company Name
Announced On
11/30/2017
Transaction Type
Venture Equity
Amount
$76,500,000
Round
Series C
Investors
Proceeds Purpose
Codiak intends to use the proceeds of the Series C financing to advance its initial product candidates into clinical trials, and to continue to develop the company's transformational exosome therapeutic platform.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
500 Technology Sq. 9th Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Codiak Biosciences (Nasdaq: CDAK) is developing multiple platforms for both therapeutic and diagnostic applications based on a growing appreciation for exosome biology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Douglas Williams
Chief Financial Officer
Linda Bain
Vice President
Sriram Sathy
Vice President
Benny Sorensen
VP - Manufacturing
Konstantin Konstantinov
Browse more venture capital transactions:
Prev: 11/30/2017: Spot.IM venture capital transaction
Next: 11/30/2017: Thrive Global venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs